Advertisement
Australia markets closed
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    95,044.32
    +4,708.31 (+5.21%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     
  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

Kimberly-Clark (KMB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Kimberly-Clark (KMB) reported $5.15 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 0.9%. EPS of $2.01 for the same period compares to $1.67 a year ago.

The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $5.08 billion. With the consensus EPS estimate being $1.61, the EPS surprise was +24.84%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Kimberly-Clark performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Personal Care - Volume impact - YoY change: 2% compared to the 0.2% average estimate based on four analysts.

  • K-C Professional - Organic Sales Growth - YoY change: 2% versus -0.8% estimated by four analysts on average.

  • Personal Care - Organic Sales Growth - YoY change: 10% compared to the 4.7% average estimate based on four analysts.

  • Total Organic Sales Growth - YoY change: 6% versus 2.4% estimated by four analysts on average.

  • K-C Professional - Currency impact - YoY change: -2% versus the four-analyst average estimate of -2.7%.

  • Personal Care - Net price impact - YoY change: 7% versus the four-analyst average estimate of 3.6%.

  • Personal Care - Mix impact - YoY change: 1% versus the four-analyst average estimate of 0.9%.

  • Personal Care - Currency impact - YoY change: -9% compared to the -4.1% average estimate based on four analysts.

  • Net Sales- Personal Care: $2.71 billion versus $2.72 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.3% change.

  • Net Sales- K-C Professional: $823 million compared to the $801.30 million average estimate based on four analysts. The reported number represents a change of -2.8% year over year.

  • Net Sales- Corporate & Other: $14 million versus $10.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +40% change.

  • Net Sales- Consumer Tissue: $1.60 billion versus $1.54 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.1% change.

View all Key Company Metrics for Kimberly-Clark here>>>

Shares of Kimberly-Clark have returned +3% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Kimberly-Clark Corporation (KMB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research